PHYSICIAN PRESCRIBING PATTERNS IN INNOVATIVE ANTIDEPRESSANTS IN THE UNITED STATES: THE CASE OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Jia IC, Rohab SH, Jia JF
University of Michigan, Ann Arbor, MI, USA

OBJECTIVES: The use of innovative antidepressants has been growing as many were introduced since 1990s. However, physician prescribing patterns in innovative antidepressants is unclear. This study disentangled the impacts of sociological factors, such as physician, patient, and health-care system factors, on the patterns and dynamics of adopting innovative antidepressants for major depressive disorder (MDD) in the US.

METHODS: A retrospective 15-year cross-sectional study was conducted using the 1993–2007 National Ambulatory Medical Care Survey representing 125,605,444 MDD patients. The Heckman two-step model was used to capture physician's two-stage prescribing decision and to correct sample selection bias. First, logistic regression was applied to examine the impact of sociological factors on whether an antidepressant is prescribed. Second, a conditional logistic regression was used to capture physician's choice of innovative versus older antidepressants. RESULTS: A total of 71.22% MDD patients were prescribed an antidepressant. Physicians who were primary care physicians, non-owner of health-care settings, practiced in Western and non-metropolitan areas, and had not seen patients before were more likely to prescribe innovative antidepressants (all P < 0.0001). Patients who were younger, non-Hispanic, belong to HMOS, and took patient education were more likely to receive innovative antidepressants (all P < 0.001.) Trend analyses revealed that physicians who were owners of non-solo practice, practiced in Midwestern, Northeastern and metropolitan areas were decreasing likelihood of prescribing innovative antidepressants over time. Patients who were non-white, non-black and non-Hispanic, and enrolled in Medicaid had increasing likelihood of receiving innovative antidepressants over time. CONCLUSIONS: The patterns of physician prescribing innovative antidepressants for MDD patients in the United States varied with sociological factors. Patient characteristics, physicians characteristics, and health-care system factors had impacts on physician's decision on choosing innovative antidepressants. Prescribing patterns also varied over time.

HEALTH SCIENCE STUDENTS ATTITUDES TOWARD RESEARCH AND IT'S IMPLICATIONS TO TEACHING

Maya S
Manipal University, Manipal, Karnataka, India

OBJECTIVES: To assess the attitudes toward research of health science students and discuss its implications to teaching. Attitudes about research are important because they may influence the quality of research. In particular, attitudes and beliefs about research can affect the extent to which they will develop useful critical thinking skills. Health science students usually tend to view research methods courses negatively. However, an understanding of these attitudes is necessary to help instructors facilitate the learning of research methodology, by enabling them to create more positive attitudes toward such courses. METHODS: The attitudes toward research of students of health science (mean age 24.79), Manipal University, were measured using the instrument: the Attitudes toward Research. The ATR consists of 32 items constituting five subscales: research usefulness, research anxiety, positive attitudes, relevance to life, difficulty of research. Data was summarized by computing descriptive statistics. RESULTS: Students of health science scores more than 70% of the maximum score on the subscales -research usefulness, positive attitudes and relevance to life. They scored less than 50% of the maximum score on subscales -research anxiety and difficulty of research. Students expressed that estimating sample size, data analysis and interpretation are the most difficult aspects in research. CONCLUSIONS: To reduce the research anxiety and feeling of difficulty, topics relating to statistics are to be taught in a simpler way. They should be provided practical experience through project work. Usefulness of the topics is to be emphasised through actual data analysis and interpretation relating to their field.

MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies

THE LONG-TERM UTILIZATION AND SAFETY OF BIOLOGICAL AGENTS IN TREATING RHEUMATOID ARTHRITIS PATIENTS—A POPULATION-BASED CASE STUDY IN SOUTHERN TAIWAN

Chen IC, Chen LC, Yang HY, Wu JY
Kaohsiung Medical University, Kaohsiung, Taiwan, Bureau of National Health Insurance, Kaohsiung, Taiwan

OBJECTIVES: This case study aims to evaluate the long-term utilization and safety of two biological agents - etanercept and adalimumab in treating Taiwanese rheumatoid arthritis (RA) patients. METHODS: This cohort study used a population-based claim-data from the Kaoping Division of Taiwanese National Health Insurance during March 2006 to June 2009. Adult RA outpatient were identified by diagnosis code, and followed from the first prescription date (index date) of biological agents up to two months after discontinuation (prescription stop for more than 30 days) or the end of study. Prescription continuation rate between two drugs was evaluated using Kaplan-Meier survival curves and compared by the log-rank test. The frequencies of infectious events for new users of biological agents were also collected and the odds ratio of infectious events comparing etanercept against adalimumab were evaluated by logistic regression. RESULTS: Of all, 190 new users (mean age 53.43 ± 11.61 years; 83.68% female) were assessed. Most patients (70.53%) were prescribed biological agents in medical centers and 63.16% of them used etanercept. Total cumulative exposure time was 184,32 patient-years (145,86 patient-years in etanercept group, 38,46 patient-years in adalimumab group). Overall continuation rate for biological agents was 78.06% after 1 year, 55.04% after 2 years. The median continuation time is 836 days (95% CI 541, 972). Twenty-nine infectious events were detected; the most frequent events are pneumonia (seven events) and tuberculosis (six events). Patients who treated by etanercept had more infectious events than patients treated with adalimumab (OR: 5.99, 95% CI 1.55, 40.00). CONCLUSIONS: This study demonstrated that only half RA patients sustained their original biological therapy for more than 2 years. Furthermore, RA patients who treated with etanercept acquired higher risk of infectious events. However, it is still necessary to further find our reasons for discontinuation and to explore the causality between biological agents and infectious events.

GASTROINTESTINAL AND CARDIOVASCULAR RISK OF NONSELECTIVE NSAIDS AND COX-2 INHIBITORS IN ELDERLY PATIENTS WITH KNEE OSTEOARTHRITIS

Turajane T
Police General Hospital, Bangko, Thailand

OBJECTIVES: To evaluate the risk for gastrointestinal (GI) events and cardiovascular(CV) events in patients ≥60 years with knee osteoarthritis using NSAIDs or coxibs users. METHODS: A hospital-based retrospective cohort study was conducted. Data on prescription drug (NSAIDs, celecoxib, etoricoxib) was obtained from June 2004 to June 2007 were included if they were aged ≥60 years. Patients with a history of gastrointestinal disease or heart disease were excluded. RESULTS: A total 12,591 prescriptions from 1030 patients, an average of four prescriptions/patient/year, from June 2004 to June 2007 were included if they were aged ≥60 years. Patients with a history of gastrointestinal disease or heart disease were excluded. RESULTS: A total 12,591 prescriptions from 1030 patients, an average of four prescriptions/patient/year, were included. During follow-up, 325 patients were withdrawn from follow-up. The mean age of cohort was 69.6 years, with the majority being female (74%). Comparing celecoxib with NSAID use in logistic regression analysis, patients who received celecoxib were significantly less likely to suffer GI events than those who received NSAIDs; OR = 0.36 (95% CI 0.21–0.63, P = 0.00). Similarly, etoricoxib was less likely to cause GI events than NSAIDs; OR = 0.52 (95% CI 0.28–0.98, P = 0.04). Comparing to patients aged under 60 years, patients aged ≥70 years had a significantly higher chance of developing GI events, OR = 1.79 (95% CI 1.13–2.4) for patients aged 70–80 years and 3.36 (95% CI 1.78–5.81) for those aged >80 years. Drug exposure time, significantly increased the GI risks. For CV event, there were only three significantly associated with CV events-female (OR = 2.95, 95% CI 0.63–5.99, P = 0.01), age >60 years (OR = 2.29, 95% CI 1.57–4.32, P = 0.00), and drug exposure time (OR = 1.05, 95% CI 1.01–1.1, P = 0.00). CONCLUSIONS: Incidence of GI and CV events was lower for coxibs than for NSAIDs and celecoxib had a lower incidence than etoricoxib. Patients with advanced age and higher drug exposure time had a significant risk.

THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN

Su YI, Lin PM, Tsai IC, Soong YK
1Novartis Pharmaceuticals Corporation, Taipei, Taiwan, Taiwan; 2Chung-Gung Memorial Hospital and The Taiwanese Osteoporosis Association, Taichung, Taiwan

OBJECTIVES: To elucidate the relationship of the risk of refactorines to compliance and support with bisphosphonate therapy in Taiwan. METHODS: We conducted a retrospective claims database of Taiwan's National Health Insurance (NHI) between 2003–2006. The study subjects included all new users of bisphosphonates. Compliance was estimated using a medication possession ratio (MPR), calculated as the total days of supply divided by the number of days between the first and last dispensing plus the days of supply of the last dispensed prescription, with bisphosphonate therapy was defined as continuous use, allowing for a refill gap of 30 days. RESULTS: The refracture rates of the osteoporosis patients increased with time. The refracture rate was 5.15%, 7.36%, and 8.49% at the first, second, and third years, respectively. The refracture rate of patients with over 80% compliance was significantly lower than those with a compliance below 80% (P < 0.05). The study found that nearly half of the patients were noncompliant with therapy (MPR ≤ 80%) at as early as 3 months, and only around 30% of the patients were adherent at 1 year. The results also showed that the risk of refracture increased for patients with MPR ≤ 80%, non-persistence, older patients and patients with comorbidities such as rheumatoid arthritis, diabetes mellitus or dementia. Patients with concomitant statin medication tended to have significantly lower refracture risks than those without. CONCLUSIONS: From the study, the compliance and persistence of Taiwanese
patients is poor. In addition, the study demonstrated that the risk of refracture is associated with the compliance and persistence with bisphosphonate therapy in Taiwan. The compliance and persistence issues for osteoporosis treatment warrant much more attention.

MUSCULAR-SKELETAL DISORDERS – Cost Studies

PMS4

BURDEN OF DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA: RESULTS FROM 2009 NATIONAL HEALTH AND WELLNESS SURVEY

Ting B1, Li Z2, Annunziata K3, Li X4, Dong P4

1Pfizer, New York, NY, USA; 2Peking University People's Hospital, Beijing, China; 3KantarHealth, Princeton, NJ, USA; 4Pfizer China, Beijing, China

OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, and medical resource utilization in patients with rheumatoid arthritis (RA).

METHODS: Patients' self-reported data were collected from 2009 National Health and Wellness Survey (NHWS). Survey samples represented major urban areas in China. QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general population). Loss of work/productivity was measured by the validated Work Productivity and Activity Impairment (WPAI) questionnaire, a medical resource utilization. Medical resource utilization was calculated based on the data in 2) above and the data of wage for the engaged persons.

RESULTS: In the 13,307 survey respondents, 276 (2.1%) were diagnosed with RA (non-RA group). RESULTS: The prevalence of RA in China was 2.1% 

CONCLUSIONS: RA patients suffer from impairment in quality of life, work/productivity loss, more medical resource utilization than those without RA. A comparison of amount is made between them.

MICRO-COSTING OF JUDO-THERAPY CLINICS IN JAPAN—MULTI-CENTERED COST ANALYSIS

Tarumoto N1, Igarashi A1, Tarumoto E1, Harada T1, Fukuda T1

1Teikyo Heisei University, Tokyo, Japan; 2Tokyo Univ. Faculty of Pharmacy, Tokyo, Japan; 3Tokyo Judo-Therapy Clinic, Tokyo, Japan; 4Tokyo University, Tokyo, Japan

OBJECTIVES: In the Judo-therapeutic field, their costs are partly covered by National Health Insurance System via fee-for-service reimbursement, which does not necessarily reflect actual costs. Therefore, the actual situation of medical practice in Judo-therapy Clinics (bone-setting clinic) is analyzed by comparison between the actual costs calculated by micro-costing methods and reimbursement cost calculated by fee-for-service system.

METHODS: The basis of this study is a bidirectional evaluation of single medical intervention in terms of actual cost and reimbursed cost for single treatment with covering methods: 1) All percentages are collected from the participating bone-setting clinics for a fixed period of time; 2) Along with collection of receipts, information on the medical treatments is recorded by region with regard to “how long” and “who” performed them; 3) The tentative cost of medical intervention is calculated based on the data in 1) above and the data of wage for the engaged persons.

METHODS: A Markov state transition model with 1-year cycle length was designed to simulate the cost-effectiveness of seven osteoporosis treatment interventions, compared with calcium and vitamin D, in Thai post-menopausal women aged 50–70 years. The model health states were categorized as osteopenia/no fracture, hip fracture, vertebral fracture, post-hip fracture, post-vertebral fracture and death. Treatment effects were measured in terms of number of fractures avoided, number of life-years gained and quality-adjusted life-years (QALY) gained. Cost-effectiveness was defined as an ICER of less than 300,000 Baht (an incremental cost of ≤300,000 Baht for an outcome of no fracture by year). RESULTS: 1) For patients with no prior fracture (primary prevention), zoledronic acid is cost-effective at ≥267 years, alendronate, risedronate and ibandronate at ≥270 years. 2) For patients with prior vertebral fracture (secondary prevention), zoledronic acid is cost-effective at ≥50 years, alendronate, risedronate and ibandronate at ≥35 years, raloxifene and raloxifene at ≥260 years; and 3) For patients with prior non-vertebral fractures, zoledronic acid is cost-effective at ≥260 years, alendronate at ≥35 years, and risedronate and ibandronate at ≥270 years. CONCLUSIONS: Zoledronic acid, followed by other bisphosphonates, is the most cost-effective treatment option for both primary and secondary fracture prevention in Thai postmenopausal women with osteoporosis. This findings should be implemented in the government policy for selecting appropriate anti-osteoporotic drugs and reimbursement support strategy for Thai postmenopausal women with osteoporosis.